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X-ray crystallographyOver a decade has passed since the elucidation of the ﬁrst X-ray crystal structure of any complex II homolog.
In the intervening time, the structures of ﬁve additional integral-membrane complex II enzymes and three
homologs of the soluble domain have been determined. These structures have provided a framework for
the analysis of enzymological studies of complex II superfamily enzymes, and have contributed to detailed
proposals for reaction mechanisms at each of the two enzyme active sites, which catalyze dicarboxylate
and quinone oxidoreduction, respectively. This review focuses on how structural data have augmented our
understanding of catalysis by the superfamily. This article is part of a Special Issue entitled: Respiratory complex
II: Role in cellular physiology and disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
During respiration, living cells use oxidation–reduction reactions to
harvest energy from their environment and convert this into a conve-
nient chemical form, most frequently ATP. This commonly requires the
formation of a transmembrane electrochemical gradient as an intermedi-
ate step. Mitochondrial aerobic respiration catalyzes oxidative phosphor-
ylation, which is just one example of an energy-harvesting bioenergetic
pathway. In oxidative phosphorylation, electrons from environmental
chemicals (food) are transferred into the electron transport chain and
eventually to molecular oxygen. Mitochondrial aerobic respiration uses
ﬁve membrane-spanning complexes for this process, and electrons
enter the electron transport chain through either complex I or complex
II. Complex II bridges the processes of oxidative phosphorylation with
the Krebs cycle, thus linking these two energy harvesting processes in
higher organisms. In addition, membrane-spanning homologs of
complex II participate in both aerobic respiration and bacterial anaerobic
respiration with fumarate as the terminal electron acceptor [1].
2. Structures of complex II enzymes
2.1. Global architecture of the complex II superfamily
Complex II enzymes couple two distinct chemical reactions: the
reversible oxidoreduction of succinate and fumarate, catalyzed in aQFR, quinol:fumarate reductase
tory complex II: Role in cellular
l rights reserved.soluble domain, and the reversible oxidoreduction of quinol and quinone,
which is catalyzed in a membrane-spanning domain. Members of the
superfamily have increased reaction rates and improved catalytic efﬁ-
ciency when catalyzing the reaction in one direction, and have been
given distinct names to reﬂect this [2]. Succinate:quinone oxidore-
ductases (SQRs, succinate dehydrogenases, SdhABCD) are kinetically
advantaged to oxidize succinate and reducequinone, a reaction important
for aerobic respiration. Conversely, quinol:fumarate reductases (QFRs,
fumarate reductases, FrdABCD) are kinetically advantaged to catalyze
the reverse reaction, i.e. to reduce fumarate and oxidize quinol (Table 1).
No matter the preferred direction of the reaction, complex II su-
perfamily enzymes share a global architecture with a large soluble
domain and a smaller integral-membrane domain (Fig. 1). The solu-
ble domain contains two polypeptide chains; a large ﬂavoprotein
(Fp; SdhA or FrdA; ~600 amino acids) that covalently attaches ﬂavin
adenine nucleotide (FAD) and is organized around a Rossmann fold,
and an iron–sulfur protein (Ip; SdhB or FrdB; ~250 amino acids)
that coordinates a 2Fe:2S, a 3Fe:4S, and a 4Fe:4S cluster and has do-
mains related to bacterial and plant-type ferredoxins. The complex
II enzymes are grouped into a superfamily based upon sequence
similarity between the SdhA/FrdA (ﬂavoprotein) and SdhB/FrdB
(iron–sulfur protein) subunits of the soluble domain, which generally
contain >40% sequence identity. By contrast, the membrane-spanning
subunits (SdhC/FrdC and SdhD/FrdD) differ substantially across the su-
perfamily (Fig. 2). Indeed, the membrane-spanning domain of complex
II enzymes may contain 0, 1 or 2 membrane-spanning subunits with 5
or 6 transmembrane helices and 0, 1, or 2 b-type hemes. As a result, it
has been hypothesized that the membrane-spanning regions have dis-
tinct evolutionary origins. Thus, the complex II superfamily has been
further divided into four subfamilies (types A–E) that are classiﬁed
Table 1
Kinetic parameters of succinate oxidation and fumarate reduction by SQR and QFR
enzymes. Comparison of kcat, Km, and catalytic efﬁcient reveals a distinct kinetic advantage
for each enzyme in one direction. Numbers are taken fromMaklashina (2006) J. Biol. Chem
[28].
Succinate oxidation Fumarate reduction
kcat
(s−1)
Kmsucc
(μM)
kcat/Km
(μM−1 s−1)
kcat
(s−1)
Kmfum
(μM)
kcat/Km
(μM−1 s−1)
E. coli
SQR
110.0±4.0 110±10 1000 2.0±0.2 100±12 20
E. coli
QFR
30.0±0.5 550±38 54 250±10 30±0.5 232
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hemeswithin themembrane spanning region [3,4]. More recent phylo-
genetic analysis based upon the sequence of the iron–sulfur protein
(SdhB or FrdB) is consistent with the evolutionary grouping of these
subtypes but suggests further evolutionary subgroups in subfamilies A
and C [4].
To date, the X-ray crystal structures of six complex II superfamily
enzymes have been determined [5–10]. These structures represent
three subfamilies: subfamily B (one membrane-spanning polypeptide
with ﬁve helices and two b-type hemes, exempliﬁed by theWolinella
succinogenes QFR [6]), type C (two membrane spanning polypeptides
that each have three membrane-spanning helices, exempliﬁed by the
E. coli [7], porcine [8], and avian [9] SQRs, and the Ascaris suumQFR [10]),
and subfamily D (twomembrane spanning polypeptides each containing
three helices and no b-type heme, exempliﬁed by the E. coli QFR [5]).
Despite the sequence and cofactor differences of the membrane-
spanning domain, at a global level the members of these subfamilies
appear structurally similar (Fig. 1), and the membrane-spanning re-
gions between subfamily B and subfamily C have surprisingly high
structural similarity (for example, an RMS deviation of 1.7 Å between
W. succinogenes FrdC and avian SdhC/D over 130 Cα atoms) despite aFig. 1. Overviewof structures of complex II. Shown are (A) the E. coliQFR in complexwith fumar
[7]) from the same perspective. The E. coli SQR has been demonstrated to be a trimer, but for c
purple, the iron sulfur protein (FrdB/SdhB) is colored light blue, and themembrane-spanning sub
carbons and bonds. Substrates or inhibitors are shownwith dark blue carbons and bonds and inc
to the E. coli SQR), within the dicarboxylate interconversion active site of the ﬂavoprotein, and s
within each Q-site. Inspection of these two structures shows that the soluble domains are sim
panel (A), the positions of the menaquinol molecules in the ﬁgure were modeled from their ex
(PDB ID: 1L0V [5]).lack of detectable sequence identity when using automated sequence
alignments [11].
An important impact of this global architecture is the formation
and separation of the two distinct active sites (Fig. 1), one within
the soluble domain that catalyzes the 2H+/2e− interconversion of
succinate and fumarate (dicarboxyate interconversion site; Fig. 3),
and one within the membrane spanning regions where quinone and
quinol (collectively termed “Q” here if an oxidation state is not implied)
are interconverted (Q-site; Fig. 2D–F). These two active sites are sepa-
rated by ~40 Å, but chemical turnover between them is coupled since
electrons that are the products of one reaction become the substrates
of the second reaction. Electrons are transferred between these active
sites via the three Fe:S clusters coordinated to the SdhB or FrdB subunit
(Fig. 1).
Intriguingly, X-ray crystal structures have demonstrated that the
oligomerization state of complex II proteins differs both across the su-
perfamily and across subfamilies with “monomers” [5,8–10] (where a
monomer is deﬁned as the SdhA/B/C/D or FrdA/B/C/(D)), dimers [6],
and trimers [7] all observed to date. The impact of the differences in
oligomerization is not yet understood, however it is clear that the
chemical reactionproceeds through themonomer. Thus, oligomerization
may have evolved independently in different subfamily members to
promote protein stability, or perhaps as amethod to improve the packing
of these enzymes into the biological membrane.
2.2. Structures of quinol:fumarate reductases
X-ray crystal structures of QFRs from E. coli [5] (Fig. 1) and
W. succinogenes [6] provided the ﬁrst high-resolution information
about the complex II superfamily and represent subfamilies D and B, re-
spectively. The crystal structure of the QFR from the eukaryotic parasite
A. suumhas only recently beendetermined [10] and belongs to subfamily
C. As anticipated, these three enzymes each have similar folds in the
soluble domains. Interestingly, the membrane spanning domains,ate (PDB ID: 3P4P [34]) and (B) the E. coli SQR in complexwith oxaloacetate (PDB ID: 1NEK
larity, only the monomer is shown. In each case, the ﬂavoprotein (FrdA/SdhA) is colored
units (FrdC&FrdD/SdhC&SdhD) are colored red and green. Cofactors are shownwith yellow
lude the substrate, fumarate (bound to the E. coliQFR), and inhibitor, oxaloacetate (bound
ubstrate menaquinol (bound to the E. coliQFR) and ubiquinone (bound to the E. coli SQR)
ilar in structure and cofactor composition while the membrane domains differ in both. In
perimentally identiﬁed positions in the structure of the E. coli QFR in complex with citrate
Fig. 2. Membrane spanning subunits from complex II subfamilies. (A)W. succinogenes QFR (PDB ID: 2BS4 [6]; subfamily B) (B) Avian SQR (PDB ID: 1YQ3 [9]; subfamily C) (C) E. coli QFR
(PDB ID 1L0V: [5]; subfamily D). Figure panels (A)–(C) weremade following alignment of the ﬂavoprotein of each complex, thus observed differences in helix packing do not reﬂect dif-
ferences in the view. The functional Q-site is highlightedwith a box. Coloring is the same as in Fig. 1. (D)–(F) A close-up viewof the functional Q-site for (D)W. succinogenesQFR; (E) Avian
SQR (for consistency with the text, the numbering is for the E. coli SQR enzyme, and can be cross-referenced to the avian numbering in Table 3); (F) E. coli QFR. In each case, the view has
been rotated such that interacting residues are clearly observed. In (D), the rotation is 70° around the x-axis and 30° around the y-axis. In (E) the rotation is 180° around the x-axis and 60°
around the y-axis. In (F), the rotation is 30° around the x-axis, 180° around the y-axis, and 30° around the z-axis. Residues within 5 Å are highlighted and hydrogen-bonding interactions
are shownwith gray dots. There are no hydrogen-bonding interactions between theW. succinogenesQFR and the 2,3-dimethyl-1,4-napthoquinonemolecule. Instead, π-stackingwith the
side chain Phe-C65 and with the heme porphyrin may contribute to binding.
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four-helix bundle [12,13]. However, there are striking differences
in the structures of the membrane spanning domains (Fig. 2A–C)
that reﬂect these being classiﬁed into different subfamilies. In speciﬁc,
these differ in the number of membrane-spanning polypeptides
(two for the E. coli and A. suum enzymes, one for theW. succinogenes
enzyme), number of membrane-spanning helices (six for the E. coli
and A. suum enzymes, ﬁve for theW. succinogenes enzyme), the presence
of b-type heme (absent for the E. coli enzyme, one b-type heme in the
A. suum enzyme, two b-type hemes in the W. succinogenes enzyme),
the location of the Q-site (proximal for the E. coli and A. suum
enzymes, distal for the W. succinogenes enzyme), and the identity of
the quinol used as the electron donor (menaquinol in the E. coli and
W. succinogenes enzymes and rhodoquinol in the A. suum enzyme).
2.3. Structures of succinate:quinone oxidoreductases and mitochondrial
complex II
The structure of the E. coli SQR was the ﬁrst subfamily C SQR to be
determined (Fig. 1) [7]. This was followed several years later with the
determinationof the structures of twomitochondrial complex II enzymes,
those of the porcine [8] and avian [9] SQR complexes, both puriﬁed from
native tissue. Each of these enzymes contains four polypeptide chains. As
anticipated by the classiﬁcation within the complex II superfamily, the
soluble domains of bacterial SQR and mitochondrial complex IIs are sim-
ilar in fold. However, the membrane-spanning subunits of bacterial and
mitochondrial SQRs also display structural similarity to each other (and
to the A. suum QFR, despite the kinetically favored direction of thereaction), reﬂecting the grouping of these enzymes into a subfamily. For
example, the SdhC and SdhD subunits of porcine and avian SQR are struc-
turally nearly identical, with an rms deviation of Cα atoms 0.8 Å for the
SdhC subunit and 0.5 Å for the SdhD subunit. The membrane-spanning
regions of the vertebrate mitochondrial enzymes each display somewhat
greater structural deviations from the A. suum, QFR and the E. coli SQR, the
latter of which contains a large insert between TM1 and TM2 of the SdhC
subunit as compared to the other three subfamily C members. However,
these structural differences in the A. suum QFR and the E. coli SQR are
located away from the functional regions of the protein (Fig. 4A).
Indeed, the architecture immediately surrounding the b-type heme
and Q-site (Fig. 4B,C, Table 3) is very strongly conserved across the
structurally characterized enzymes in subfamily C [11].
2.4. Soluble homologs of SdhA/FrdA (the ﬂavoprotein)
Soluble homologs of the complex II ﬂavoprotein catalyze
α,β-dehydrogenase reactions. Of the known ﬂavoprotein homologs,
the soluble fumarate reductase from Shewanella ﬁrgidimarina is the
best characterized both structurally and biochemically [14–23],
with signiﬁcant structural work on both the soluble fumarate reduc-
tase from Shewanella putrefaciens [24] and the L-aspartate oxidase
from E. coli [25,26] also reported. Neither the Fcc3 fumarate reduc-
tases nor L-asparate oxidase contains sequence regions similar to
the iron protein or the membrane subunits of the complex II super-
family. Instead, both of the Shewanella soluble fumarate reductases
contain a single polypeptide chain with sequence analysis predicting
a domain similar to the ﬂavoprotein (FrdA/SdhA) subunit of the
Fig. 3. The dicarboxylate-interconverting active site of complex II enzymes. A close-up
view of the FAD-containing active site of the E. coli SQR (PDB ID: 2WDQ; [36]) is shown
with the position of the substrate modeled by removing the O2 from the malate-like
intermediate. Backbone atoms of the ﬂavoprotein are colored purple, side chains
discussed in-text are highlighted with gray carbons and bonds, the fumarate is
shown with blue carbons and bonds, and the FAD is shown with yellow carbons and
bonds. Hydrogen-bonding interactions between side chains and the substrate are
shown with gray dotted lines. The proposed pathway of hydride transfer between the
N5 of the FAD and the C2 of substrate is shownwith a cyan dotted line, and the proposed
pathway of proton transfer is shown with a green dotted line. Side chain numbering
corresponds to the E. coli QFR.
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chrome. As a result, these soluble fumarate reductases are also known
as Fcc3 cytochromes. By contrast, the E. coli L-aspartate oxidase, which
catalyzes the oxidation of L-aspartate as the ﬁrst step in NAD+ biosyn-
thesis [27], does not contain a peripheral domain housing redox cofac-
tors. Despite these architectural differences, investigations of the
soluble ﬂavoprotein homologs have been key for elucidating mecha-
nisms of dicarboxylate oxidoreduction in complex II. These investiga-
tions have been aided by high expression levels, puriﬁcation protocols
that do not require detergents, reasonably straightforward biophysical
properties, and the ability of crystals of these ﬂavoprotein homologs
to diffract to high-resolution.3. Structure-based mechanism of dicarboxylate interconversion
3.1. Overall chemical reaction
Prior to the availability of any structure of a complex II family
member, the basic chemical steps of fumarate reduction by QFRs
had been delineated. Brieﬂy, fumarate reduction proceeds via a
two-step mechanism. A hydride is ﬁrst transferred from the N5
atom of reduced FAD to the C2 atom of the fumarate double bond
(Fig. 3). In the subsequent step, a proton is transferred from a side
chain to the C3 of the fumarate carbanion, completing the reaction.
The catalytically active form of the enzyme is regenerated when FAD
undergoes a 2e−/1H+ reduction. In the integral-membrane complex II
family members, the electrons for the FAD reduction are derived from
menaquinol oxidation and are transferred from the Q-site to thedicarboxylate site via the Fe:S clusters in the iron protein subunit.
Re-protonation of the FAD likely uses a protein-based proton shuttle.
The succinate oxidation reaction is less well characterized, but
should proceed by approximately the same reaction steps in the reverse
order, with the exception that an anionic ﬂavin semiquinone is detect-
able during enzyme turnover [28]. An important aspect of succinate
oxidation by complex II family members is the requirement for the
FAD to be covalently attached to the Nε atom of a conserved histidine
residue via an 8α-N(3)-histidyl-linkage [29,30], which raises the reduc-
tion potential of the cofactor ~150 mV (from−219 mV to−55 mV in
E. coli) [31]. This covalent linkage is only observed in true complex II
family members and not in the soluble ﬂavoprotein homologs. The
mechanism of covalent attachment of the FAD to the protein hasn't
been delineated, but FAD insertion may be facilitated by a complex
II-speciﬁc assembly factor termed Sdh5 in yeast [32], and SdhE in
bacteria [33].
The structures of complex II family members have allowed the
dicarboxylate interconversion reactions to be placed into the context
of the active site architecture and have identiﬁed speciﬁc side chain
residues required for substrate binding, transition state formation,
and proton transfer. Structurally, the mechanism of fumarate reduction
has been better investigated than that of succinate oxidation. The delin-
eation of the geometric details of fumarate reduction in the complex II
superfamily draws heavily upon structure-based enzymology of the
easily expressed and biochemically manipulated E. coli QFR and the
S. frigidimarina Fcc3 soluble fumarate reductase.
3.2. Substrate binding and alignment
Crystallographic studies have helped develop hypotheses both for
the approximate geometry of the reaction intermediate and for the
formation of the transition state. SQRs, QFRs, and soluble ﬂavoprotein
homologs have been crystallized in the presence of fumarate [6,34] or
other dicarboxylates [8,9,14–17,21,24,25,34–36]. These structures
revealed that the side chains of two histidines, two arginines, and
one threonine and three backbone amide nitrogens are all within
hydrogen-bonding distance of dicarboxylate (Table 2). Thus, any of
these could contribute to substrate binding or transition state forma-
tion. For simplicity, the E. coli QFR numbering will be referred to in
this text regardless of the protein where the original experiment was
performed, but each amino acid identity can be cross-referenced to
the appropriate numbering for selected enzymes with available struc-
tures in Table 2. All of the side chains within the active site (His-A232,
Thr-A244, Arg-A287, His-A355, and Arg-A390,) have been investigated
by site-directed mutagenesis. Site-speciﬁc substitution of residues
equivalent to His-A232 His-A355 or Arg-A390 alters both kcat and the
Km for fumarate [14,15,37], suggesting that they could be involved in
turnover. However, crystallographic studies on the S. frigidimarina Fcc3
soluble fumarate reductase indicated that the inﬂuence of the histidine
residues on kcat was likely the result of active site reorganization [14].
Thus, onemay speculate that these residues of the FAD-binding domain
instead contribute to the binding of substrate. By comparison, Thr-A244
and Arg-A287 appeared to be of primary importance for the catalytic
mechanism as monitored by assessing the inﬂuence of substitution on
kcat/Km [15,37,38].
Co-structures of complex II homologs with fumarate [6,34] have
revealed that the substrate binds with the C2–C3 double bond aligned
along the C(4a)–N5 bond of the FAD cofactor [34] (Fig. 1). This parallel
alignment of bonds has been predicted to maximize the HOMO–LUMO
overlap via an orbital steering mechanism [34], and is one of several
mechanisms proposed to facilitate hydride transfer from the N5 of
FAD. Interestingly, molecules that are commonly classiﬁed as competi-
tive inhibitors but can act as alternative substrates show a similar align-
ment of the transformed bond along the C(4a)–N5 of the FAD; in
comparison, competitive inhibitors that are not acted upon by the
enzyme do not display this bond alignment [34].
Fig. 4. The membrane-spanning domain of subfamily C enzymes. (A) Maximum deviations (in Å) of Cα atoms from the E. coli, porcine, and avian SQR and the A. suum QFR mapped
onto the membrane-spanning subunits of the E. coli SQR (PDB ID: 2WDQ; [36]). Regions where the deviation of Cα atoms is 0.5–1.5 Å are colored black; 1.5–2.5 Å are colored gray,
2.5–3.5 Å are colored blue, 3.5–4.5 Å are colored green, 4.5–5.5 Å are colored yellow, and >5.5 Å are colored red. The regions of greatest structural difference (red) are located on
the distal side of the membrane, and regions near the heme and Q-site are well conserved, with rms deviations around 1 Å. (B) The locations of ubiquinone from porcine SQR
(magenta), avian SQR (yellow), E. coli SQR (green), and rhodoquinol from A. suum QFR (cyan) are superimposed within the binding pocket of the avian SQR (PDB ID:1YQ3 [9]).
Chains are colored using the same scheme as in Fig. 3, and side chain numbering is for the E. coli SQR, but can be cross-referenced to other enzymes in Table 3. (C) The location
of ubiquinone (green) and the inhibitor atpenin-A5 (blue) modeled within the binding pocket of the avian SQR (PDB ID:1YQ3 [9]) highlights the difference in location between
the Q1 and Q2 binding sites.
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The central double bond of fumarate normally constrains this
dicarboxylate to a planar conformation. However, co-structures of
fumarate bound to the E. coli,W. succinogenes, or A. suum QFR showed a
distinct twisting of the carboxylate groups with respect to each other
[6,10,34] (Fig. 1A). A similarly twisted conformation is observed in the
many co-structures of complex II superfamily enzymes [8,9,34–36] or
soluble ﬂavoprotein homologs [14–17,21,24,25] with dicarboxylate
competitive inhibitors (Fig. 1B). A twisted conformation of fumarate is
hypothesized to strain the double bond to make it more amenable
to reduction [6,34,38] and is a secondmechanism proposed to promote
hydride transfer.
One controversial hypothesis for how the enzyme twists fumarate
involves interdomain movement. Like many enzyme active sites, theTable 2
Selected residues lining the dicarboxylate active site in complex II ﬂavoprotein homologs w
E. coli E. coli Porcine Avian A. suum W. succinoge
QFR SQR SQR SQR QFR QFR
Residues located on the FAD-binding domain (lock-and-key, substrate binding residues)
Side chains
His-A232 His-A242 His-A254 His-A253 His-A276 His-A257
His-A355 His-A354 His-A365 His-A364 His-A387 Arg-A369
Arg-A390 Arg-A399 Arg-A409 Arg-A408 Arg-A432 Arg-A404
Backbone
Gly-A50 Gly-A51 Gly-A63 Gly-A62 Gly-A85 Gly-A49
Ser-A393 Gly-A402 Ala-A412 Ala-A411 Ala-A435 Gly-A407
Residues located on the capping domain (induced ﬁt, catalytic residues)
Side chains
Thr-A244 Thr-A254 Thr-A266 Thr-A265 Thr-A288 Thr-A269
Arg-A287 Arg-A286 Arg-A298 Arg-A297 Arg-A320 Arg-A301
Backbone
Glu-A245 Glu-A255 Glu-A267 Glu-A266 Glu-A289 Glu-A270dicarboxylate interconverting active site of complex II and speciﬁcally
the location of both Thr-A244 and Arg-A287 is at the interface between
two domains. In the complex II ﬂavoprotein, these domains have been
termed the FAD-binding domain and the capping domain [5]. The pres-
ence of FAD and dicarboxylate appears to inﬂuence the orientation of
these two domains with respect to each other in the various crystal
structures of complex II and ﬂavoprotein homologs [9], with the
structures lacking bound substrate or cofactor generally having the
more open interdomain orientations [6,23,26], while those with in-
hibitors or substrate bound generally having intermediate or closed
interdomain orientations [5,9,35,39].
The most open conformation is observed in the structure of
L-aspartate oxidase crystallized without the FAD cofactor [26] and in
this conformation a tunnel is opened between domains. This tunnel
should allow easy access of the substrate to the dicarboxylate activeith available structures.
nes S. frigidimarina L-Asp oxidase Proposed role
Fcc3
His-365 His-244 Substrate binding
His-504 His-351 Substrate binding
Arg-544 Arg-386 Substrate binding, polarization
Gly-170 Gly-51 Substrate binding
Gly-547 Ser-389 Substrate binding
Thr-377 Thr-259 Transition state stabilization
Arg-402 Arg-290 Proton shuttle, substrate polarization
Glu-378 Glu-260 Transition state stabilization
653T.M. Iverson / Biochimica et Biophysica Acta 1827 (2013) 648–657site. In the open conformation, the binding pocket lined by residues
orthologous to His-A232 His-A355 and Arg-A390 is pre-formed, but
residues Thr-A244 and Arg-A287 are not aligned for catalysis.
Both the likelihood of interdomain motion and the inﬂuence of
Thr-A244 and Arg-A287 on the catalytic mechanism have been inves-
tigated. The earliest evidence for the importance of interdomain
alignment during catalysis was performed prior to the determination
of the structure of any complex II family member. This early study
identiﬁed a reactive thiol equivalent to Cys-A247 in the E. coli QFR.
The modiﬁcation of the residue equivalent to Cys-A247 with sulfhydryl
reagents showed signiﬁcant inhibition of enzyme activity, and this res-
idue could be protected frommodiﬁcation by the inclusion of substrates
[40–45]. This motivated the prediction that Cys-A247 was an active site
residue. Mutagenesis studies later demonstrated that Cys-A247 was
not, in fact, required for enzymatic function [46,47], however, substitu-
tion of the adjacent Arg-A248 resulted in a loss of catalytic activity [47].
The structure of the E. coli QFR [5] later demonstrated that these amino
acids are not within the active site, but instead located at the interface
between the FAD-binding and capping domains.
Further evidence for interdomain alignment being important for
catalysis comes from the examination of disease-associated mutations
in the human SQR. Themutation of the amino acid equivalent in position
to Gly-A464, which is located between the FAD-binding and capping-
domains and is predicted to inﬂuence interdomain dynamics [11], is asso-
ciated with a debilitating neurodegenerative disease known as Leigh's
syndrome in humans [48]. The patientwith this substitution had reduced
succinate oxidase activity in ﬁbroblasts suggesting that altering the
interdomain association inﬂuences enzyme turnover.
These studies are consistent with site-directed mutagenesis of the
E. coli QFR that alters Thr-A234 of the interdomain hinge (Fig. 5B). A
structure of the FrdA T234A variant demonstrated that this mutation
stabilized the open conformation of the enzyme, which is anticipated
to be catalytically incompetent since the active site residues Thr-A244
and Arg-A287 would not be appropriately aligned [9]. Indeed this
mutation reduced catalytic efﬁciency 400-fold [38].
Finally, the introduction of disulﬁde bonds between the FAD-binding
and capping domains of the S. frigidimarina Fcc3 fumarate reductase to
stabilize the closed conformation showed a 4-fold reduction in kcat and
an 11-fold reduction of kcat/Km as compared to the wild-type enzyme,
consistentwith reduced access of substrate to the closed state [19], but re-
tention of the alignment of the active site residues. Each of these lines of
evidence is consistent with interdomain rearrangements accompanying
catalysis, and speciﬁcallywith the open state of the enzyme lacking prop-
er alignment of the active site residues and therefore being catalytically
compromised. However, catalytic activity was not fully abrogated in
any of these studies, which may reﬂect limitations of the experimental
design or that the open orientation of the two domains is instead impor-
tant for FAD-insertion.
Regardless of putative enzymatic motions over the course of the
reaction coordinate, the amino acids of the capping domain are only
aligned for catalysis when the FAD-binding and capping domains are
closed around the substrate. Studies on the E. coli QFR demonstrate
that mutation of Thr-A244 reduced kcat/Km 34,000-fold, consistent
with a role for this side chain in the catalyticmechanism [38]. Combined
with interdomain closure, it was proposed that Thr-A244 torques the
substrate into the twisted conformation. Residual activity of the FrdA
T244A enzyme variant is observed and may reﬂect the contribution of
the backbone amide nitrogen of Glu-A245 to the stabilization of the
twisted reaction intermediate.
3.4. Polarization of the bound substrate
After binding within the active site, negative charge is directed from
theC2 carbon toward the C3–C4 endof thedicarboxylate by the positively
charged protein side chains [15,21]. Both Arg-A287 and Arg-A390
may contribute to this polarization. The guanido group of Arg-A390in particular is conserved in position and interacts with the C4 end of
the molecule. By comparison, in various crystal structures, the position
of Arg-A287 is somewhat variable [12], but the side chain guanido Nη1
andNη2 nitrogens are commonly positioned near the C3 and carboxylate
of C4, respectively. Site-directed substitution of the residue equivalent to
Arg-A287 on the S. frigidimarina Fcc3 identiﬁed that, subsequent to
hydride transfer, the side chain acts as a Lewis acid to stabilize the
negative charge of the carbanion at the C3 position [15].
3.5. Proton transfer from an active site arginine to the carbanion reaction
intermediate
A side-chain exhibiting a neutral pKa value (7.3 in the E. coli QFR,
7.5 in the E. coli SQR [28]) is proposed to mediate proton transfer to
the carbanion C3. Using the E. coli L-aspartate oxidase [37] and the
S. frigidimarina soluble Fcc3 fumarate reductase [14–16] as model sys-
tems, the inﬂuence of site-speciﬁc variation of each active site residue
on both structure and activity was assessed. This demonstrated that sub-
stitution of the residue equivalent to Arg-A287 to a non-ionizable residue
reduced kcat to undetectable levels, while substitution with an ionizable
residue partially restored activity [15,37]. This suggests that in addition
to its role in stabilizing the carbanion, Arg-A287 likely acts as the proton
shuttle.
Like Thr-A244, Arg-A287 is located on the capping domain, and an
appropriate interdomain orientation is likely important for the correct
alignment of this side chain. Indeed, previous analysis of the structures
of complex II ﬂavoprotein homologs shows that the position of
Arg-A287 with respect to bound substrate or inhibitor in the active
site is dependent upon the interdomain orientation, and may reﬂect
this side chains being mobile during catalytic turnover [12]. Side chain
movement is commonly observed in proton shuttling residues, and is
consistent with the role of Arg-A287 as the proton shuttle in this system.
Furthermore, if interdomain movement does occur during catalysis,
Arg-A287 would likely be solvent exposed at the end of each catalytic
cycle, facilitating reprotonation.
3.6. Summary of dicarboxylate interconversion in complex II enzymes
In summary, substrate dicarboxylate enters the active site between
domains and binds to a pre-organized site comprising three histidine
side chains, one arginine side chain, and two amide nitrogens. Binding
into this site aligns the C2–C3 bond of substrate along the C(4a)–N5
bond of the FAD cofactor. Interdomain closure aligns the Arg-A287
and Thr-A244 side chains and the Glu-A245 amide nitrogen. The latter
two of which twist the substrate into a strained reaction intermediate
while the positive charges of Arg-A287 and Arg-A390 polarize the
substrate. All of these geometric factors may facilitate hydride transfer
from FAD, forming the carbanion intermediate. Arg-A287 then acts as a
proton shuttle, completing the reaction cycle. Interestingly, this reaction
mechanism combines the lock-and-key binding of substrate to pre-
organized residues within the FAD-binding domain with induced-ﬁt
by the residues of the capping domain, speciﬁcally the side chain of
Thr-A244, the backbone amide of Glu-A245, and the side chain of
Arg-A287, as the domains change orientation.
4. Mechanisms of quinone and quinol interconversion
4.1. Overview of quinone/quinol binding and oxidoreduction
Various Q species can act as electron carriers between bioenergetic
proteins, hence the mechanism of 2H+/2e− oxidoreduction of quinone
and quinol has been characterized in several distinct systems. Q mole-
cules have two chemical positions for the oxidoreduction, the O1 and
the O4 position, each of which can donate or accept 1H+ and 1e−. In
complex II enzymes, the presence of EPR-detectable semiquinone inter-
mediates during turnover is consistent with the step-wise removal of
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ities for the protons to be transferred to bulk solvent, i.e. either the Q
substrate could bind to a site that contains two proton shuttles, one on
each side of the binding pocket, that transfer protons at different rates,
or theQ substrate could bind to a site that contains a single proton shuttle,
and following the removal of one proton, the substrate could move to
align the second position with the same proton shuttle.
With either mechanism, Q movement is likely to accompany the
reaction cycle. This makes a structural characterization of the reaction
challenging since mobile species are difﬁcult to observe by X-ray
crystallography. As a result, structural characterization of complex II
enzymes bound to competitive inhibitors, site directed mutagenesis,
and computational modeling have all been used to identify or verify
the location of the Q-sites in complex II superfamily enzymes. This
has identiﬁed spatially distinct Q-binding sites in the different sub-
families that have been termed QP (for proximal) and QD (for distal).
Even given the veriﬁcation by complementary techniques, the exact
location of Q-binding is not perfectly deﬁned in any of these enzymes,
and the identiﬁcation of the proton shuttles has either required sub-
stantial complementary experimentation, or has (sometimes) not
been proposed.
4.2. Menaquinol oxidation and ubiquinone reduction by the E. coli QFR
The E. coli QFR contains two integral-membrane polypeptide
chains (FrdC and FrdD), each with three membrane-spanning helices.
Site-directed mutagenesis, ﬂuorescence quench titrations, and EPR
spectroscopy are consistent with the presence of a single functional
Q-site coupled to fumarate reduction [51]. X-ray crystallographic
studies identiﬁed two regions of electron density consistent with Q
binding within the membrane [5] (Fig. 2C) and termed QP and QD,
however, only one of these sites, QP, has a location consistent with di-
rect electron transfer to the soluble domain [52] (Fig. 2F). This site is
lined with residues from the FrdB, FrdC, and FrdD subunits and is lo-
cated within 8 Å of the electron-transferring 3Fe:4S cofactor [5]. QP
was conﬁrmed as a functional site with further X-ray crystallographic
studies [53] of the E. coli QFR in complex with the quinol-blocking in-
hibitors heptyl quinolone N-oxide and 1-(p-chlorophenyl)ethyl]
4,6-dinitrophenol [54,55]. Oxidation of menaquinol at QP would re-
lease protons to the side of the membrane where fumarate reduction
occurs, which results in an electro-neutral process [56].
The E. coli QFR can bind either mena-Q or ubi-Q at the QP site [54],
however, menaquinol oxidation is believed to be physiologically coupled
to the fumarate reduction reaction in the enzyme. Investigation of the
mechanism of menaquinol oxidation has combined structural and spec-
troscopic measurements. Both FTIR spectroscopic measurements and
the crystal structure indicate that the O1 of the bound mena-Q forms
hydrogen-bonding contacts with Gln-B225Nε2, Lys-B228 Nζ and
Trp-D14 Nε1, while the O4 forms a single hydrogen-bonding contact to
Glu-C29 Oε1.
Available evidence is most consistent with the presence of two sepa-
rate proton shuttles formenaquinol oxidation atQP in the E. coliQFR.Mu-
tation of Glu-C29 to a non-ionizable residue results in the formation of an
EPR-detectablemenasemiquinone radical [49,51]. This suggests that one
proton shuttle removes a proton from theO1 of themenaquinol, but that
enzyme turnover cannot be completed. Themost parsimonious explana-
tion is that Glu-C29 normally acts as the proton shuttle from the O4 po-
sition. The only ionizable residue interacting with the O1 position is
Lys-B228. While this suggests that Lys-B228 is the proton shuttle from
the O1 position, this hasn't been rigorously demonstrated, and an
alternative is that the Q moves during turnover, such that the proton
is shuttled from the O1 position via another, as yet unidentiﬁed side
chain prior to the interaction between the menaquinol and Lys-B228.
When the E. coli QFR performs succinate oxidation, it is believed to
couple this reaction to ubiquinone reduction. Here, it has been
suggested that the O1 position of ubiquinone maintains the samehydrogen-bonding contacts as menaquinol (i.e. to Gln-B225 Nε2,
Lys-B228 Nζ and Trp-D14 Nε1). However, the quinone ring rotates
slightly such that the O4 position hydrogen-bonds to the side chain of
Arg-D28 (rather than Glu-C29) within the membrane [57]. Consistent
with this, the mutation of Glu-C29 to a non-ionizable residue results
in protein that is fully functional for ubiquinone reduction but deﬁcient
in menaquinol oxidation [57]. This minimally indicates that the proton
shuttle for menaquinol oxidation differs from that used for ubiquinone
reduction, and strongly suggests that Arg-D28 acts as the proton shuttle
for ubiquinone reduction. The limited resolution of the structures of the
E. coli QFR has prevented the accurate placement of water molecules
within the Q-site, such that the pathway of proton transfer from either
menaquinol oxidation or ubiquinone reduction to bulk solvent has not
yet been further mapped.
4.3. Menaquinol oxidation by the W. succinogenes QFR
Structural mapping of the Q-site and proton shuttle pathway in the
W. succinogenesQFR originateswith a crystal structure of this enzyme in
complex with 2,3-dimethyl-1,4-napthoquinone [58]. This redox-active
molecule is structurally similar to the menaquinone head group, and
the corresponding quinol can support QFR activity in in vitro assays.
The 2,3-dimethyl-1,4-napthoquinone binds within the FrdC subunit in
a location that is distal to the soluble domain (QD) (Fig. 2A). The location
of themenaquinol binding site within theW. succinogenesQFRwas ver-
iﬁed using a combination of computational modeling and site-directed
mutagenesis of Glu-C66 [59,60], a residue located adjacent to the bind-
ing site for 2,3-dimethyl-1,4-napthoquinone and between the QD-site
and the positive side of the membrane (Fig. 2D), and the only obvious
candidate for a proton shuttle from this site. The loss of activity in the
FrdC E66Q variant led to the proposal that the identiﬁed QD site was
functionally relevant and that the side chain of Glu-C66 acted as a
proton shuttle. The location of this proton shuttle would be antici-
pated to release protons to the positive side of the membrane,
whichwould contribute to the formation of the transmembrane elec-
trochemical gradient. However, the energy of transferrin electrons from
menaquinol to fumarate is theoretically insufﬁcient to support proton
pumping.
This apparent conundrum was reconciled with investigation of a
second integral-membrane glutamate residue, Glu-C180, which is
located in the middle of the membrane-spanning region and also
demonstrated to be critical for enzyme activity [58,61,62]. Multiple
studies are consistent with Glu-C180 and the heme propionates partic-
ipating in a second, distinct proton shuttling pathway that brings pro-
tons back along the gradient to the negative side of the membrane
[58,60,61,63–65] (Fig. 2A). When acting in conjunction with proton
shuttling from Glu-C66, this second proton shuttling pathway renders
theW. succinogenes QFR reaction cycle energetically neutral. The pres-
ence of two distinct proton shuttles with opposing directions andmedi-
ated by glutamates (E) is termed the “E-pathway hypothesis” and may
be important for function in enzymeswithin the B subfamily of complex
II enzymes [59].
4.4. Rhodoquinol oxidation by A. suum QFR
The A. suum QFR couples fumarate reduction to rhodoquinol oxida-
tion. In the structure, a rhodo-Q was identiﬁed at a site classiﬁed as QP
(Fig. 4B), and co-crystallization of the A. suum QFR with the fungicide
and competitive inhibitor ﬂutolanil conﬁrms this as a functional Q-site
[10]. The location of this site strongly suggests that it is the immediate
electron donor to the 3Fe:4S cluster.
The structural understanding of theA. suum enzyme lags behind that
of both the E. coli and W. succinogenes QFRs by 13 years, and further
in-depth studies of the structural basis for rhodoquinol oxidation by
the A. suum have not yet been performed. However, the classiﬁcation
of this enzyme into subfamily C (Fig. 2B,E, Fig. 4) and the similarity
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bers suggests that rhodoquinol oxidation might proceed by the reverse
mechanism as ubiquinone reduction in subfamily C SQRs (described
below in Section 4.5).4.5. Ubiquinone reduction by subfamily C SQRs
Nearly all of the detailed structure–function studies aimed at
identiﬁcation of the mechanism of Q oxidoreduction in subfamily C
enzymes have been performed on the E. coli SQR. However, the
strong sequence and structural conservation surrounding both the
heme and the QP site in subfamily C enzymes (Fig. 4A, Table 3) suggests
that results from the biochemical investigations of the easily-
manipulated E. coli enzyme are applicable to the remaining members
of the subfamily. For simplicity, the E. coli SQR side chain numbering
will be used in-text, but can be cross-referenced to other subfamily C
complex II enzymes in Table 3.
In subfamily C enzymes, the Q-site is classiﬁed as Qp (Fig. 2B) and
physiologically couples the reduction of ubiquinone to the oxidation of
succinate, thus contributing to the formation of the reduced quinone
pool. The binding site for the ubiquinonehead group is located at the in-
terface between the membrane and soluble regions of SQR and is lined
with residues from the SdhB, SdhC, and SdhD subunits. Only the ﬁrst
two isoprene groups of the ubiquinone are observed in crystal
structures, suggesting that the majority of the hydrophobic tail is
not speciﬁcally bound to the protein. The location of the Q-site in
subfamily C SQRs was identiﬁed with co-crystallization of ubiqui-
none with E. coli [7], avian [9], and porcine [8] SQRs, and veriﬁed
via co-crystallization studies of subfamily C enzymes with competi-
tive inhibitors of Q-binding, including 2-thenoyltriﬂuoroacetone
[8], carboxin [9,36], pentacholorophenol [36], atpenin-A5 [66], or
2-(1-methyl-hexyl)-4,6-dinitrophenol [7]. Examination of the place-
ment of ubi-Q within the structures of subfamily C complex II enzymes
(Fig. 4B) reveals differences in positioning of the head group in each
structure despite a strongly conserved architecture of the surrounding
binding pocket [7–10]. It is not clear if this difference in placement re-
ﬂects real differences in binding or if this instead reﬂects challenges in
substrate placement within ambiguous crystallographic electron density.
Interestingly, the O1 of ubi-Q makes conserved hydrogen-bonding con-
tacts to Trp-B173 Nε and Tyr-D83 OH in all structures available to date.
Corroborating this placement are studies of E. coli SQR where alteration
of Tyr-D83 by site-directed mutagenesis results in a loss of an
EPR-detectable semiquinone signal [50]. However, only the placement
of ubi-Q within the avian SQR model (and rhodo-Q within the A. suum
QFR) is consistent with any hydrogen-bonding partner for the O4 ofTable 3
Selected residues lining the Q-site in subfamily C enzymes.
E. coli
SQR
Porcine
SQR
Avian
SQR
A. suum
QFR
Notes
B-subunit
Pro-B160 Pro-B169 Pro-B169 Pro-B193
Trp-B164 Trp-B173 Trp-B173 Trp-B197 Nε H-bonds to O1 of Q
Arg-B205 Arg-B214 Arg-B214 Ly-B238
His-B207 His-B216 His-B216 His-B240 May H-bond to deeply-bound Q
C-subunit
Ser-C27 Ser-C42 Ser-C39 Ser-C72 Oγ H-bonds to Q in some
positions
Ile-C28 Ile-C43 Ile-C40 Gly-C73
Arg-C31 Arg-C46 Arg-C43 Arg-C76 Nη1 may H-bond to
deeply-bound Q
D sub-unit
Asp-D82 Asp-D90 Asp-D57 Asp-D106
Tyr-D83 Tyr-D91 Tyr-D58 Tyr-D107 OH H-bonds to O1 of Qposition, which is to the side chain analogous to Ser-C27. Site-directed
substitution of Ser-C27 results in the loss of the EPR-detectable
semiquinone signal [50], and suggests that Ser-C27 is important for sta-
bilization of this radical.
Of note is the structure between the E. coli SQR and atpenin-A5
[66] (Fig. 4C). This competitive inhibitor has been demonstrated to
bind more deeply within the QP-site than ubiquinone, prompting
computational modeling studies of the native substrate within the
Q-site. These calculations were consistent with Q being able to bind in
two distinct locations, with Q1 observed in the crystal structures avail-
able to-date, andQ2 closely superimposingwith the atpenin-A5 binding
location. In the Q2 position, the O3 methoxy position of ubiquinone is
proposed to approach and hydrogen-bond to the side chain of
His-B207, while the O4would form a hydrogen-bondwith Ser-C27. At-
tempts to validate the Q2 position with site-directed mutagenesis of
His-B207 show that substitution of this side chain has limited effects
on enzyme turnover [67]. Furthermore, this position is commonly mu-
tated in fungi resistant to carboxin [68]. Taken together, this suggests
that the Q2 position may be of limited importance for catalytic activity,
but that this part of the Q-site is required for the binding of some com-
petitive inhibitors of ubiquinone catalysis.
It has remained challenging to propose a clear side-chain mediated
proton shuttle from either the Q1 or the Q2-position, motivating the
suggestion that ordered water molecules were major components of
the proton-shuttling pathway. However, site-directed mutagenesis of
side chains proposed to order water molecules near the Q-site have
hadmeasurable but limited effects onQ turnover [36,69]. An alternative
proposal is that the Tyr-D83 and Trp-B173 are sufﬁciently close to the
surface of the phospholipid bilayer that theymay be exposed to solvent
and not require an additional proton shuttling pathway. Clearly, further
investigation of Q-turnover in subfamily C enzymes is warranted.
Subfamily C enzymes contain a single b-type heme within the
membrane spanning subunits. The location of the b-type heme is
off-pathway from the electron transfer cofactors and this cofactor is not
involved in direct electron transfer between the dicarboxylate active
site and the Q-site [7]. Indeed, the converse is true, electrons appear to
require transfer through theQ-site if they are to reduce heme [50]. Inves-
tigation of a variant E. coli SQR lacking the b-type heme shows reduced
stability of the complex when extracted into detergent, but retains all
other physiological properties of the enzyme, including redox cycling
[70]. Further, the lowering of the reduction potential or complete ab-
sence of the b-type heme does not increase the formation of reactive
radical species [70,71], which suggests that the heme does not act as
a sink for excess electrons. Accordingly, the functional signiﬁcance of
this cofactor remains somewhat mysterious.
5. Summary and conclusions
The wealth of information from 14 years of structural investigations
on complex II enzymes has complemented 100 years of biochemical
investigation on complex II enzymes and has contributed to the devel-
opment of detailed mechanistic proposals for catalysis at the multiple
active sites. The conserved oxidoreduction of succinate and fumarate
is common to all complex II superfamily members, and as anticipated,
the investigation of dicarboxylate oxidoreduction in any homolog has
yielded insights into the mechanisms of complex II superfamily. By
comparison, the mechanism for Q oxidoreduction appears to be some-
what unique in enzymes belonging to each subfamily, reﬂecting how
independent evolution has resulted in a diverse set of solutions for a
single chemical problem.
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